Antenatal corticosteroid therapy in late preterm infants: evidence and controversies
10.3760/cma.j.cn113903-20190415-00261
- VernacularTitle:晚期早产产前糖皮质激素应用的证据和争议
- Author:
Haiqing LENG
1
;
Jianguo ZHOU
Author Information
1. 新疆维吾尔自治区喀什地区第二人民医院新生儿科 844000
- From:
Chinese Journal of Perinatal Medicine
2020;23(5):316-320
- CountryChina
- Language:Chinese
-
Abstract:
Compared with term infants, late preterm infants, defined as the gestational age of 34 +0-36 +6 weeks, have a significantly higher incidence of neonatal respiratory diseases. Antenatal corticosteroid (ACS) therapy is of great importance in promoting lung maturation and improving prognosis in preterm infants. It has been recommended as a routine approach in the treatment of preterm infants less than 34 gestational weeks. However, its efficacy and potential side effects in late preterm infants remain inconclusive. We review the pharmaceutical mechanisms, clinical research data, current guidelines, controversies, potential complications of ACS therapy in late preterm birth to inform current clinical practice and address future research directions.
